奥沙利铂市场规模、竞争格局和市场预测——2029 年

市场概览

奥沙利铂是一种抗癌药物，适用于治疗结直肠癌。它是一种铂类药物，与顺铂和卡铂类似。奥沙利铂的作用是干扰细胞中 DNA 的发育，阻止它分裂成新细胞并导致细胞死亡。

奥沙利铂市场动态

奥沙利铂市场的增长预计将受到结直肠癌发病率增加、生活方式改变、老年人口增加、肿瘤领域广泛研究等因素的推动，从而在预测期内提振全球奥沙利铂市场。预计是主要因素。

结直肠癌发病率上升预计将在预测期内推动全球奥沙利铂市场

全球结直肠癌病例数正在增加。美国癌症协会 (ACS) 估计，2019 年美国将登记约 101,420 例结肠癌新病例和约 44,180 例直肠癌新病例。根据国家癌症研究所的数据，2018 年英国诊断出约 1,735,350 例新癌症病例。到 2037 年，意外诊断出的结直肠癌病例预计将增加 27.3%，达到 672,400 例。这种增加归因于低纤维饮食、肥胖、酒精和烟草消费。结直肠病例数量的增加将刺激整个全球奥沙利铂市场。

越来越多地使用生物製剂和靶向疗法可能会阻碍全球结直肠癌药物市场

生物製剂和靶向疗法的使用增加可能会阻碍市场增长。生物疗法帮助身体的免疫系统对抗癌症，而不是削弱身体免疫系统的化学物质。靶向治疗可以阻止结直肠癌的生长和转移，即使是在化学药物不起作用的 IV 期。例如，FDA批准了用于治疗结直肠癌的靶向疗法，例如贝伐珠单抗、西妥昔单抗和帕尼单抗。生物製剂和靶向疗法相对于传统化学品的优越性可能会对市场产生负面影响。

COVID-19 影响分析

由于 COVID-19 大流行的爆发，全球奥沙利铂市场由于生产和销售环节的壁垒而下滑。疫情导致药品生产减少，因为除口罩、消毒剂和换气扇外，所有药品都已关闭。所以在这次大流行期间，製造的药品数量比以前少了。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

• 第 3 章：按配方类型划分的市场细分
• 按适应症划分的市场细分
• 按应用划分的市场细分
• 按分销渠道细分的市场
• 按地区划分的市场细分

第四章市场动态

• 市场影响因素
  • 司机
    • 结直肠癌的发病率增加
  • 约束
    • 增加生物製剂和靶向疗法的使用
  • 商机
  • 影响分析

第五章行业分析

• 波特的五力分析
• 害虫分析
• 供应链分析
• 定价分析
• 监管分析
• 保险报销分析
• 未满足需求分析

第 6 章 COVID-19 分析

• COVID-19 市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章，按配方类型分类

• 冻干粉
• 水溶液

第八章按功效

• III 期结肠癌的辅助治疗
• IV 期结直肠癌药物
• 其他

第9章应用

• 结肠癌
• 胃癌
• 卵巢癌

第 10 章分销渠道

• 医院药房
• 零售药房
• 在线药店

第11章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲地区
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第12章竞争格局

• 主要发展和战略
• 公司股票分析
• 产品基准
• 值得关注的重点公司
• 拥有颠覆性技术的公司
• 初创公司

第 13 章全球奥沙利铂市场：公司概况

• Pfizer Inc
  • 公司概况
  • 产品组合和说明
  • 主要亮点
  • 财务摘要
• Sanofi
• Fresenius Kabi D
• Dr. Reddy's laboratory
• Sun Pharmaceutical Industries Ltd
• Qilu Pharmaceutical Co., Ltd
• Teva Pharmaceuticals USA, Inc
• Jiangsu Aosaikang Pharmaceutical Co. Ltd
• Mylan
• Hospira
• Nanjing Phamaceutical Factory
• Jiangsu Hengrui Medicine
• Lunan Pharmaceutical
• Hisun Pharmaceutical
• Hainan Jinrui Pharmaceutical

第14章 DataM

Market Overview

The global Oxaliplatin market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Oxaliplatin is an anti-cancer medication indicated to treat colorectal cancer. It is a platinum-based drug belonging to the same family as that of cisplatin and carboplatin. Oxaliplatin acts by interfering with the development of DNA in a cell, thereby stopping it from dividing into new cells and kills it.

Oxaliplatin Market Dynamics

The oxaliplatin market growth is driven by the growing incidence of Colorectal cancers, and changing lifestyle, increasing geriatric population and extensive research in field of oncology are the major factors that are anticipated to boost the global oxaliplatin market during the forecast period.

Increasing incidence of Colorectal Cancers, is expected to drive the global oxaliplatin market during the forecast period.

The number of colorectal cancer cases worldwide has been increasing. As per the American Cancer Society (ACS) estimates, there will be around 101,420 new colon cancer cases, and around 44,180 new cases of rectal cancer are registered in the USA in 2019. As per the National Cancer Institute data, nearly 1,735,350 new cases of cancer were diagnosed in the U.K in 2018. The diagnosed incident colorectal cancer cases are expected to increase by 27.3% to 672,400 cases by 2037. This increase can be attributed to a low-fiber diet, obesity, alcohol, and tobacco consumption. The increase in the number of colorectal cases will add to the overall global oxaliplatin market.

Increased usage of biologics and targeted therapies is likely to hamper the global colorectal cancer drugs market.

Increased usage of biologics and targeted therapies is likely to hamper the market growth. Biologic therapy helps the body's immune system fight against cancer rather than chemical drugs, which reduces the body's immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV, where chemical drugs are ineffective. For instance, the FDA has approved some targeted therapies to treat colorectal cancer, including bevacizumab, cetuximab, and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for global oxaliplatin market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the drugs were manufactured less compared to previous years, during the outbreak.

Segment Analysis

The lyophilized powder segment is expected to hold largest share in this market segment

Lyophilization is a freeze-drying process, which is performed to extend the shelf life of a product. The oxaliplatin lyophilized powder injection is prepared using a specific lyophilization process to increase the stability of the drug, reduce the risk of side effects, and ensure a high degree of clinical usage. However, it is slightly expensive than the aqueous solution. The global average selling price of 100 mg intravenous injection is around USD 84 - USD 500. Sanofi offers ELOXATIN in a lyophilized powder form.

The adjuvant treatment of stage III colon cancer segment is expected to hold largest share in this market segment

In patients with stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine combined with oxaliplatin (FOLFOX and XELOX) are considered the standard treatment and reduces the risk of recurrence and mortality, with a treatment duration that may be shortened from 6 to 3 months in certain situations allowing to limit toxicities, especially cumulative sensitive neuropathy.

The colorectal cancer segment is expected to hold largest share in this market segment

Colorectal cancer is the second leading cause of cancer deaths in the U.S. As per the data by the National Cancer Institute, nearly 1,735,350 new cases of cancer were diagnosed in the U.K. and 609,640 people were succumbed to the disease in 2018. According to the American Society of Clinical Oncology (ASCO), in 2019, nearly 45,600 adults in the U.S. were diagnosed with colorectal cancer.

The hospital pharmacies segment is expected to hold largest share in this market segment

The hospital pharmacies held the largest share in the global oxaliplatin market. This is mainly owing to increasing number of patients suffering from colorectal cancers which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, Increasing number of oncologists and healthcare professionals, specializing in the diagnosis of cancer at an early stage and providing proper treatment is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.

Geographical Analysis

North America region holds the largest market share of global oxaliplatin market

North America held a major share of the global oxaliplatin market and is expected to continue its dominance during the forecast period. In North America, the oxaliplatin market is projected to be driven by an increase in colorectal cancer cases and raising awareness of various treatment modalities for cancer. As per the U.S. Department of Health and Human Services in U.S., colorectal cancer represented 8.3% of all new cancer cases in 2019. According to the American Cancer Society, Inc. (ACS), in 2020, nearly 104,610 new colon and 43,340 cases of rectal cancer are expected to be diagnosed in the U.S., with nearly 53,200 deaths from colorectal cancer.

Competitive Landscape

The global oxaliplatin market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Sanofi, Pfizer Inc, Fresenius Kabi D, Dr. Reddy's laboratory, Sun Pharmaceutical Industries Ltd, Qilu Pharmaceutical Co., Ltd, Teva Pharmaceuticals USA, Inc, Jiangsu Aosaikang Pharmaceutical Co. Ltd, Mylan, Hospira, Nanjing Phamaceutical Factory, Jiangsu Hengrui Medicine, Lunan Pharmaceutical, Hisun Pharmaceutical, Hainan Jinrui Pharmaceutical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Oxaliplatin Market Key Companies to Watch:

Pfizer Inc.

• Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

• Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

• Product: OXALIPLATIN injection, for intravenous use 50 mg (5 mg/mL) or 100 mg (5 mg/mL) in a single-dose vial for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced colorectal cancer.

Why Purchase the Report?

• Visualize the composition of the oxaliplatin market segmentation by formulation type, application, indication, distribution channel and by region highlighting the key commercial assets and players.

• Identify commercial opportunities in oxaliplatin market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of oxaliplatin market - level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global oxaliplatin market report would provide an access to an approx. 69 market data table, 61 figures and 200 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Formulation Type
• 3.2. Market Snippet by Indication
• 3.3. Market Snippet by Application
• 3.4. Market Snippet by Distribution channel
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Driver
    • 4.1.1.1. Increasing incidence of Colorectal Cancers
  • 4.1.2. Restraints:
    • 4.1.2.1. Increased usage of biologics and targeted therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. PEST Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis
• 5.6. Reimbursement Analysis
• 5.7. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Formulation Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation type Segment
  • 7.1.2. Market Attractiveness Index, By Formulation type Segment
• 7.2. Lyophilized Powder^*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 7.3. Aqueous Solutions

8. By Indication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment
  • 8.1.2. Market Attractiveness Index, By Indication Segment
• 8.2. Adjuvant Treatment of Stage III Colon Cancer^*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 8.3. Treatment of Stage IV Colorectal Cancer
• 8.4. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Colorectal Cancer^*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 9.3. Stomach cancer
• 9.4. Ovarian cancer

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.1.2. Market Attractiveness Index, By Distribution channel
• 10.2. Hospital Pharmacies^*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  • 11.1.2. Market Attractiveness Index, By Region

• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico

• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe

• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America

• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific

• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Product Benchmarking
• 12.4. Key Companies to Watch
• 12.5. Company with disruptive technology
• 12.6. Start Up Companies

13. Global Oxaliplatin Market - Company Profiles

• 13.1. Pfizer Inc^*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Sanofi
• 13.3. Fresenius Kabi D
• 13.4. Dr. Reddy's laboratory
• 13.5. Sun Pharmaceutical Industries Ltd
• 13.6. Qilu Pharmaceutical Co., Ltd
• 13.7. Teva Pharmaceuticals USA, Inc
• 13.8. Jiangsu Aosaikang Pharmaceutical Co. Ltd
• 13.9. Mylan
• 13.10. Hospira
• 13.11. Nanjing Phamaceutical Factory
• 13.12. Jiangsu Hengrui Medicine
• 13.13. Lunan Pharmaceutical
• 13.14. Hisun Pharmaceutical
• 13.15. Hainan Jinrui Pharmaceutical

^*(LIST NOT EXHAUSTIVE)

14. DataM Intelligence

• 14.1. Appendix
• 14.2. About Us and Services
• 4.3. Contact Us

List of Tables

• Table 1: Global Oxaliplatin Market Value, By Formulation Type, 2021,2025 & 2029($ Million)
• Table 2: Global Oxaliplatin Market Value, By Application, 2021,2025 & 2029($ Million)
• Table 3: Global Oxaliplatin Market Value, By Indication, 2021,2025 & 2029($ Million)
• Table 4: Global Oxaliplatin Market Value, By Distribution Channel, 2021,2025 & 2029($ Million)
• Table 5: Global Oxaliplatin Market Value, By Region, 2021,2025 & 2029($ Million)
• Table 6: Global Oxaliplatin Market Value, By Formulation Type, 2021,2025 & 2029($ Million)
• Table 7: Global Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
• Table 8: Global Oxaliplatin Market Value, By Application, 2021,2025 & 2029($ Million)
• Table 9: Global Oxaliplatin Market Value, By Application, 2018-2029($ Million)
• Table 10: Global Oxaliplatin Market Value, By Indication, 2021,2025 & 2029($ Million)
• Table 11: Global Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
• Table 12: Global Oxaliplatin Market Value, By Distribution Channel, 2021,2025 & 2029($ Million)
• Table 13: Global Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
• Table 14: Global Oxaliplatin Market Value, By Region, 2021,2025 & 2029($ Million)
• Table 15: Global Oxaliplatin Market Value, By Region, 2018-2029($ Million)
• Table 16: North America Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
• Table 17: North America Oxaliplatin Market Value, By Application, 2018-2029($ Million)
• Table 18: North America Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
• Table 19: North America Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
• Table 20: North America Oxaliplatin Market Value, By Country, 2018-2029($ Million)
• Table 21: South America Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
• Table 22: South America Oxaliplatin Market Value, By Application, 2018-2029($ Million)
• Table 23: South America Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
• Table 24: South America Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
• Table 25: South America Oxaliplatin Market Value, By Country, 2018-2029($ Million)
• Table 26: Europe Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
• Table 27: Europe Oxaliplatin Market Value, By Application, 2018-2029($ Million)
• Table 28: Europe Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
• Table 29: Europe Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
• Table 30: Europe Oxaliplatin Market Value, By Country, 2018-2029($ Million)
• Table 31: Asia-Pacific Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
• Table 32: Asia-Pacific Oxaliplatin Market Value, By Application, 2018-2029($ Million)
• Table 33: Asia-Pacific Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
• Table 34: Asia-Pacific Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
• Table 35: Asia-Pacific Oxaliplatin Market Value, By Country, 2018-2029($ Million)
• Table 36: Middle East & Africa Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
• Table 37: Middle East & Africa Oxaliplatin Market Value, By Application, 2018-2029($ Million)
• Table 38: Middle East & Africa Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
• Table 39: Middle East & Africa Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
• Table 40: Pfizer Inc: Overview
• Table 41: Pfizer Inc: Product Portfolio
• Table 42: Pfizer Inc: Key Developments
• Table 43: Fresenius Kabi D: Overview
• Table 44: Fresenius Kabi D: Product Portfolio
• Table 45: Fresenius Kabi D: Key Developments
• Table 46: Sanofi: Overview
• Table 47: Sanofi: Product Portfolio
• Table 48: Sanofi: Key Developments
• Table 49: Dr. Reddy's laboratory: Overview
• Table 50: Dr. Reddy's laboratory: Product Portfolio
• Table 51: Dr. Reddy's laboratory: Key Developments
• Table 52: Sun Pharmaceutical Industries Ltd: Overview
• Table 53: Sun Pharmaceutical Industries Ltd: Product Portfolio
• Table 54: Sun Pharmaceutical Industries Ltd: Key Developments
• Table 55: Qilu Pharmaceutical Co., Ltd: Overview
• Table 56: Qilu Pharmaceutical Co., Ltd: Product Portfolio
• Table 57: Qilu Pharmaceutical Co., Ltd: Key Developments
• Table 58: Teva Pharmaceuticals USA, Inc: Overview
• Table 59: Teva Pharmaceuticals USA, Inc: Product Portfolio
• Table 60: Teva Pharmaceuticals USA, Inc: Key Developments
• Table 61: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Overview
• Table 62: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Product Portfolio
• Table 63: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Key Developments
• Table 64: Mylan: Overview
• Table 65: Mylan: Product Portfolio
• Table 66: Mylan: Key Developments
• Table 67: Hospira: Overview
• Table 68: Hospira: Product Portfolio
• Table 69: Hospira: Key Developments

List of Figures

• Figure 1: Global Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
• Figure 2: Global Oxaliplatin Market Share, By Application, 2021 & 2029(%)
• Figure 3: Global Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
• Figure 4: Global Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
• Figure 5: Global Oxaliplatin Market Share, By Region, 2021 & 2029(%)
• Figure 6: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 7: Global Oxaliplatin Market Y-o-Y Growth, By Formulation Type, 2021 & 2029(%)
• Figure 8: Lyophilized Powder: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 9: Aqueous Solutions: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 10: Global Oxaliplatin Market Y-o-Y Growth, By Application, 2021 & 2029(%)
• Figure 11: Colorectal cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 12: Stomach Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 13: Ovarian Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 14: Global Oxaliplatin Market Y-o-Y Growth, By Indication, 2021 & 2029(%)
• Figure 15: Adjuvant Treatment of Stage III Colon Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 16: Treatment of Stage IV Colorectal Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 17: Others: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 18: Global Oxaliplatin Market Y-o-Y Growth, By Distribution Channel, 2021 & 2029(%)
• Figure 19: Hospital Pharmacies: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 20: Retail Pharmacies: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 21: Online Pharmacies: Global Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 22: Global Oxaliplatin Market Y-o-Y Growth, By Region, 2021 & 2029(%)
• Figure 23: North America Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 24: North America Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
• Figure 25: North America Oxaliplatin Market Share, By Application, 2021 & 2029(%)
• Figure 26: North America Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
• Figure 27: North America Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
• Figure 28: North America Oxaliplatin Market Share, By Country, 2021 & 2029(%)
• Figure 29: South America Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 30: South America Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
• Figure 31: South America Oxaliplatin Market Share, By Application, 2021 & 2029(%)
• Figure 32: South America Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
• Figure 33: South America Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
• Figure 34: South America Oxaliplatin Market Share, By Country, 2021 & 2029(%)
• Figure 35: Europe Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 36: Europe Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
• Figure 37: Europe Oxaliplatin Market Share, By Application, 2021 & 2029(%)
• Figure 38: Europe Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
• Figure 39: Europe Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
• Figure 40: Europe Oxaliplatin Market Share, By Country, 2021 & 2029(%)
• Figure 41: Asia-Pacific Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 42: Asia-Pacific Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
• Figure 43: Asia-Pacific Oxaliplatin Market Share, By Application, 2021 & 2029(%)
• Figure 44: Asia-Pacific Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
• Figure 45: Asia-Pacific Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
• Figure 46: Asia-Pacific Oxaliplatin Market Share, By Country, 2021 & 2029(%)
• Figure 47: Middle East & Africa Oxaliplatin Market Value, 2018-2029($ Million)
• Figure 48: Middle East & Africa Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
• Figure 49: Middle East & Africa Oxaliplatin Market Share, By Application, 2021 & 2029(%)
• Figure 50: Middle East & Africa Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
• Figure 51: Middle East & Africa Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
• Figure 52: Pfizer Inc: Financials
• Figure 53: Fresenius Kabi D: Financials
• Figure 54: Sanofi: Financials
• Figure 55: Dr. Reddy's laboratory: Financials
• Figure 56: Sun Pharmaceutical Industries Ltd: Financials
• Figure 57: Qilu Pharmaceutical Co., Ltd: Financials
• Figure 58: Teva Pharmaceuticals USA, Inc: Financials
• Figure 59: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Financials
• Figure 60: Mylan: Financials
• Figure 61: Hospira: Financials